Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 67877-444

5 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 67877-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dalfampridine-equa (Dalfampridine Equa)

Dalfampridine-equa (Dalfampridine Equa)
A mathematical formula representing creatinine clearance (Crcl), calculated as (140 minus age) multiplied by weight in kilograms, divided by serum creatinine in mg/dL times 72. This formula is related to kidney function assessment commonly referenced in clinical settings.*
FDA Label Image

Dalfampridine-struc (Dalfampridine Struc)

Dalfampridine-struc (Dalfampridine Struc)
Chemical structure diagram of dalfampridine showing a pyridine ring with an amino group (NH2) attached. This represents the active ingredient dalfampridine.*
FDA Label Image

Dalfampridine-fig1 (Dalfampridine Fig1)

Dalfampridine-fig1 (Dalfampridine Fig1)
A bar graph comparing the percentage of patients with various average percent increases in walking speed from baseline between a placebo group (N=72) and a group taking Dalfampridine Extended-release Tablets 10 mg b.i.d. (N=224). The x-axis shows average percent increase thresholds (≥ 0% to ≥ 60%), and the y-axis shows the percentage of patients, illustrating higher improvement percentages in the Dalfampridine group across thresholds.*
FDA Label Image

Dalfampridine-fig2 (Dalfampridine Fig2)

Dalfampridine-fig2 (Dalfampridine Fig2)
A bar chart comparing the percentage of patients achieving various thresholds of average percent increase in walking speed from baseline between placebo and Dalfampridine extended-release tablets 10 mg b.i.d. The chart shows patient percentages on the vertical axis and walking speed improvement thresholds on the horizontal axis, demonstrating greater improvements for the Dalfampridine group compared to placebo.*
FDA Label Image

Dalfampridine-10mg-60tablets (Dalfampridine 10mg 60tablets)

Dalfampridine-10mg-60tablets (Dalfampridine 10mg 60tablets)
Label for Dalfampridine Extended-release Tablets 10 mg, film-coated oral tablets, supplied as a 60-tablet bottle. The label includes storage instructions, dosage form, and manufacturer information, showing Ascend Laboratories, LLC as the distributor and Alkem Laboratories Ltd. as the manufacturer. It has a barcode and a note for pharmacists to dispense the accompanying Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.